Lantern Pharma is trading 7.21% up at $0.92 on October 5 after a steep recent decline; no confirmed catalyst for the rebound was found.
- A September 30 registered direct offering raised approximately $4 million gross through shares and pre-funded warrants priced around $1.09; it is background, not a confirmed cause.
- Broader markets were mixed, with no clear same-direction move to explain the gain.